ARCT
NASDAQ · Biotechnology
Arcturus Therapeutics Holdin
$6.72
-0.10 (-1.47%)
Open$6.86
Previous Close$6.82
Day High$6.99
Day Low$6.69
52W High$24.17
52W Low$5.85
Volume—
Avg Volume618.7K
Market Cap206.92M
P/E Ratio—
EPS$-2.82
SectorBiotechnology
Analyst Ratings
Strong Buy
18 analysts
Price Target
+293.0% upside
Current
$6.72
$6.72
Target
$26.41
$26.41
$16.23
$26.41 avg
$33.18
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 92.23M | 125.37M | 31.39M |
| Net Income | -73,964,644 | -90,482,777 | -5,088,256 |
| Profit Margin | -80.2% | -76.2% | -16.2% |
| EBITDA | -82,343,055 | -106,328,533 | -7,015,778 |
| Free Cash Flow | — | — | -5,929,972 |
| Rev Growth | -26.4% | -26.4% | +5.3% |
| Debt/Equity | — | — | 0.28 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $261.07 | +3.99% | 126.9 | 461.26B |
| AMGN | Amgen Inc | $374.15 | +3.55% | 25.9 | 201.93B |
| GILD | Gilead Sciences Inc | $131.27 | +4.21% | 17.7 | 162.98B |
| VRTX | Vertex Pharmaceuticals Inc | $528.04 | +6.03% | 30.4 | 131.79B |
| REGN | Regeneron Pharmaceuticals | $654.27 | +4.73% | 15.5 | 68.59B |
| ALNY | Alnylam Pharmaceuticals Inc | $312.78 | +3.68% | 72.4 | 41.76B |